Search Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapyHematologic NeoplasmsProtocol groupAggressive LymphomasIndolent LymphomasTransplantationDiseaseChronic Lymphocytic Leukemia / Small Lymphocytic LymphomaMantle Cell LymphomaNHL, B-Cell Type, Diffuse Large CellNHL, B-Cell Type, Follicular Grade I-IIIaNHL, B-Cell Type, Follicular grade IIIbNHL, B-Cell Type, IndolentNHL, B-Cell Type, Lymphoplasmocytic / Waldenström's diseaseNHL, B-Cell Type, Marginal Zone LymphomaSubgroupunfitICD10C82.-C82.7C82.9C83.0C83.1C83.3C88.0-C91.1-MeSHLeukemia, Lymphocytic, Chronic, B-CellLymphoma, B-Cell, Marginal ZoneLymphoma, FollicularLymphoma, Mantle-CellWaldenstrom MacroglobulinemiaSequenceGADOLIN: OBIN1000/BEND90, foll. Lymphoma °I-IIIa, C1 (PID710) -|- C2-6 (PID724) -|- maint. (PID725)RITU375/LENA20, ind. B-NHL ind. (PID309) -|- LENA20 maint. (PID329)ChemotherapyChemo-substanceAcalabrutinibBendamustineCarmustineChlorambucilCytarabineDexamethasoneEtoposideIdelalisibLenalidomideMelphalanObinutuzumabRituximabZanubrutinibChemo-substanceAcalabrutinibBendamustineCarmustineChlorambucilCytarabineDexamethasoneEtoposideIdelalisibLenalidomideMelphalanObinutuzumabRituximabZanubrutinibChemo-substanceAcalabrutinibBendamustineCarmustineChlorambucilCytarabineDexamethasoneEtoposideIdelalisibLenalidomideMelphalanObinutuzumabRituximabZanubrutinibChemo-substanceAcalabrutinibBendamustineCarmustineChlorambucilCytarabineDexamethasoneEtoposideIdelalisibLenalidomideMelphalanObinutuzumabRituximabZanubrutinibNo. Substances126 RadiotherapySupportive therapySupportive substanceAcetylsalicylic acidAciclovirBalanced Crystalloid SolutionCotrimoxazoleDalteparinDexamethasoneDimetindenFosaprepitantGranisetronPantoprazoleParacetamolPegfilgrastimPrednisoloneSupportive substanceAcetylsalicylic acidAciclovirBalanced Crystalloid SolutionCotrimoxazoleDalteparinDexamethasoneDimetindenFosaprepitantGranisetronPantoprazoleParacetamolPegfilgrastimPrednisoloneSupportive substanceAcetylsalicylic acidAciclovirBalanced Crystalloid SolutionCotrimoxazoleDalteparinDexamethasoneDimetindenFosaprepitantGranisetronPantoprazoleParacetamolPegfilgrastimPrednisoloneSupportive substanceAcetylsalicylic acidAciclovirBalanced Crystalloid SolutionCotrimoxazoleDalteparinDexamethasoneDimetindenFosaprepitantGranisetronPantoprazoleParacetamolPegfilgrastimPrednisoloneNo. Substances12467Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationFirst lineRelapse therapySecond lineseveral possibleTherapy phaseInductionMaintenanceSalvageTherapy intentioncurativedisease controlpalliativeRisksAnemia Hb below 8g/dlAtrial FibrillationBleedingCardiotoxicityDiarrheaDysphagiaEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)FatigueFebrile NeutropeniaHypertensionHyponatremiaHypotensionIncrease AminotransferasesInfectionsInfusion ReactionNeutropeniaPneumoniaPneumonitisPruritusPyrexiaRashSepsisThrombocytopenia below 50 000/µlUpper Respiratory Tract Infection only studiesPublicationAuthorArdeshna KMGopal AKKirschey SOpat SRobinson KSRummel MJSehn LSehn LHStrati PTuscano JMDiseaseCD20-positives indolentes B-Non-Hodgkin-Lymphom, rezidiviert oder therapierefraktär, nach mindestens 1 rituximabhaltiger Therapie, ECOG 0-2Foll. L. °I-II, Marginalzonen-L., kleines lymphozyt. L., ECOG 0-2, mind. eine Vortherapiefoll. L. °I-II, Marginalzonen-L., kleines lymphozyt. Lymphom, mind. eine Vortherapie, ECOG 0-2Foll. L. °I-IIIa, kleines lymphozyt. L., Marginalzonenl., lymphoplasmoyt. L., Drittlinie bei Rituximab- u Alkylanz-RefraktäritätMarginalzonenlymphom, therapierefraktär oder rezidiviert, mindestens eine Vortherapie, ECOG 0-2MCL, follikuläres (Grad 1und 2), lymphoplasmozytisches, Marginalzonen-, kleines lymphozytisches Lymphom, Std. III u IV, ErstlinieMCL, follikuläres, lymphoplasmozytisches, kleines lymphozytisches u Marginalzonen-Lymphom, 2.-4.-LinieNon-Hodgkin Lymphom, low-grade, nicht-aggressiv, Stadium III-IVRefraktäres oder rezidiviertes Marginalzonenlymphom, Zweitlinie, ECOG 0-2rezidivierte aggressive B-NHL, 18-65 Jahre, ECOG 0-2Rituximab refraktäre indolente B-NHL, ECOG 0-2OriginBritish Columbia Cancer Agency and the University of British Columbia, Vancouver, Canada, GADOLIN trialBritish National Lymphoma Investigation, CRC and UCL Cancer Trials Centre, London, UKCentre for Lymphoid Cancer, British Columbia Cancer Agency and the University of British Columbia, Vancouver, British Columbia, GAUSS StudyDepartment of Haematology, Oncology and Pneumology, University Medical School of the Johannes Gutenberg University MainzDepartment of Medicine, Division of Medical Oncology, University of Washington School of Medicine, USAMonash University, Clayton, Victoria, Australia, MAGNOLIA trialQE II Helath Sciences Centre, Halifax, Nova Scotia, CanadaStudy Group indolent Lymphomas (StiL)The University of Texas MD Anderson Cancer Center, Houston, Texas, USA, ACE-LY-003UC Davis Cancer Center, Sacramento, USAProtocols in Revision 14 protocols foundProtocols under revision.Acalabrutinib 100, Marginal Zone Lymphoma (PID2402)Chlorambucil 10, B-Non-Hodgkin Lymphoma (PID2334)Idelalisib 150, indolent B-non-Hodgkin Lymphoma (PID308)Obinutuzumab 1000 / Bendamustine 90 - Obinutuzumab 1000 Maintenance, follicular lymphoma °I-IIIa (PID725)Obinutuzumab 1000 / Bendamustine 90, follicular lymphoma °I-IIIa, cycle 1 (PID710)Obinutuzumab 1000 / Bendamustine 90, follicular lymphoma °I-IIIa, cycle 2-6 (PID724)Obinutuzumab 1000, B-non-Hodgkin Lymphoma, maintenance (PID2341)Obinutuzumab 1000, B-Non-Hodgkin Lymphoma, Induction (PID2340)R-DexaBEAM - Rituximab 375 / Dexamethasone 8 / Carmustine 60 / Etoposide 75 / Cytarabine 100 / Melphalan 20, B-Non-Hodgkin Lymphoma (PID1006)Rituximab 375 / Bendamustine 90, indolent B-non-Hodgkin Lymphoma and Mantle Cell Lymphoma, first-line (PID271)Rituximab 375 / Bendamustine 90, indolent B-non-Hodgkin Lymphoma and Mantle Cell Lymphoma, second line (PID270)Rituximab 375 / lenalidomide 20 - Lenalidomide 20 maintenance, indolent B non-Hodgkin Lymphoma induction (PID329)Rituximab 375 / Lenalidomide 20, indolent B non-Hodgkin Lymphoma, induction (PID309)Zanubrutinib 160, marginal zone lymphoma (PID2227)